Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization ...

Fresolimumab is under clinical development by Sanofi and currently in Phase II for Non-Small Cell Lung Cancer.

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, ...

It’s not intended to prevent lung cancer, but rather treat patients with the most common type, non-small-cell lung cancer by ...

KB707 administered via inhalation demonstrated early evidence of monotherapy activity that was most pronounced in patients with advanced non-small cell lung cancer (NSCLC), where an objective response ...

A home-based exercise program boosted exercise capacity and quality of life among patients after lung cancer surgery but did not improve self-reported physical function, a new study found.

In 17 heavily pretreated NSCLC EGFR mutant (EGFR mut) patients the combination shows an ORR of 24% and a DCR of 71%; tumor ...

The latest announcement is out from AstraZeneca ( (AZN) ).

The FDA has approved a new drug called ensartinib for adults with a type of lung cancer called ALK-positive non-small-cell lung cancer (NSCLC).

Woman from Central Texas thought she had allergies. Then she learned she had lung cancer, although she never smoked.